

# Final Agenda 50<sup>th</sup> meeting of the Committee for Risk Assessment

## 9 - 13 September 2019 and 16 - 20 September 2019

## ECHA Conference Centre (Annankatu 18, Helsinki)

## Monday 9 September starts at 14.00 Friday 13 September breaks at 13.00 Monday 16 September resumes at 14.00 Friday 20 September ends at 13.00

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

RAC/A/50/2019 For adoption

## Item 3 – Declarations of conflicts of interest to the Agenda

## Item 4 – Appointment of (co-)rapporteurs

a) Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, DNEL/dose-response relationships, Article 95(3) requests and Article 77(3)(c) requests

### Item 5 – Report from other ECHA bodies and activities

a) Report on RAC 49 action points, written procedures and update on other ECHA bodies

RAC/50/2019/01 Room document For information b) RAC workplan for all processes

For information

c) Annual update of RAC accredited stakeholders' list

The Secretariat will update you on the requests from stakeholder observers to attend RAC meetings since the last review of the RAC stakeholder's. You will be invited to agree on the updated list of the accredited stakeholder organisations to RAC for this year.

RAC/50/2019/02 (restricted) For agreement

## Item 6 – Harmonised classification and labelling (CLH)

## 6.1 General CLH issues

a) CLP- suggested changes in the timing of the Appointment of rapporteurs

RAC/50/2019/03 For information

## 6.2 CLH dossiers

## A. Hazard classes for agreement without plenary debate (fast-track)

4-methylpentan-2-one: acute toxicity (all routes of exposure), serious eye damage / eye irritation, skin corrosion / irritation, skin sensitisation, STOT RE, STOT SE 3 (narcotic effects), germ cell mutagenicity, toxicity to reproduction, aspiration hazard, EUH066

trinexapac-ethyl (ISO): environmental hazards

clomazone (ISO): acute toxicity (all routes of exposure), serious eye damage /eye irritation, skin corrosion / irritation, skin or respiratory sensitisation, STOT RE, germ cell mutagenicity, carcinogenicity, aspiration hazard, environmental hazards

citric acid: physical hazards (explosives, flammable solids, self-reactive substances, pyrophoric solids, self-heating substances, substances which in contact with water emit flammable gases, oxidising solids, corrosive to metals), acute toxicity (all routes of exposure), serious eye damage / eye irritation, respiratory or skin sensitisation, germ cell mutagenicity, carcinogenicity, toxicity to reproduction, STOT RE, environmental hazards

desmedipham (ISO): environmental hazards

phenmedipham (ISO): environmental hazards

triticonazole: acute toxicity (dermal and inhalation routes of exposure), STOT SE, skin corrosion/irritation, serious eye damage/irritation, respiratory sensitisation and skin sensitisation, environmental hazards

trifloxystrobin (ISO): environmental hazards

esfenvalerate (ISO): acute toxicity (oral route of exposure), skin sensitisation, germ cell mutagenicity, environmental hazards

ethametsulfuron-methyl (ISO): acute toxicity (all routes of exposure), STOT SE, STOT RE , serious eye damage / eye irritation, skin corrosion /irritation, skin

sensitisation, germ cell mutagenicity, carcinogenicity, environmental hazards, hazardous to the ozone layer

emamectin benzoate (ISO): physical hazards (explosives, flammable solids, selfreactive substances, pyrophoric solids, self-heating substances, substances which in contact with water emit flammable gases, oxidising solids), acute toxicity (all routes of exposure), serious eye damage / eye irritation, skin corrosion / irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, STOT RE (except SCLs), environmental hazards

#### B. Hazard classes for agreement with plenary debate

- 1) Methyl salicylate
- 2) 4-methylpentan-2-one
- 3) Clomazone (ISO)
- 4) Citric acid
- 5) Desmedipham
- 6) Phenmedipham (ISO)
- 7) Triticonazole
- Boric acid [1]; Diboron trioxide [2]; Tetraboron disodium heptaoxide, hydrate [3]; Disodium tetraborate, anhydrous [4]; Orthoboric acid sodium salt [5]; Disodium tetraborate decahydrate [6]; Disodium tetraborate pentahydrate [7]
- 9) Trifloxystrobin( ISO)
- 10)Esfenvalerate (ISO)
- 11) ethametsulfuron-methyl (ISO)
- 12) dimethomorph (ISO)
- 13)Emamectin benzoate (ISO)
- 14)1,2-epoxy-4-epoxyethylcyclohexane
- 15)mecoprop-P (ISO)

#### For discussion and adoption

#### Item 7 – Restrictions

#### 7.1 Restriction Annex XV dossiers

- a) Conformity check and key issues discussion
  - 1) Calcium cyanamide in fertilisers

#### For agreement

- b) Opinion development
  - 1) Skin sensitisers in textile first draft opinion

- 2) Perfluorohexane-1-sulphhonic acid, its salts and related substances first draft opinion
- 3) Siloxanes (D4, D5 and D6) second draft opinion
- 4) Formaldehyde and formaldehyde releasers second draft opinion
- 5) Microplastics second draft opinion

#### For discussion

- 6) N,N-dimethylformamide- final draft opinion
- 7) Cobalt salts final draft opinion

#### For adoption

#### Item 8 – Authorisation

#### 8.1 General authorisation issues

- a) Update on incoming/future applications
- b) OPnEO consideration of approaches to risk assessment

#### For information/discussion

#### 8.2 Authorisation applications

- a) Discussion on key issues
  - 1. 27 applications for authorisation from May 2019 submission window (OPE/NPE, CTPht, Cr(VI))

#### For discussion

- b) Agreement on draft opinions
  - 1. CT\_TES (1 use)
  - 2. SC\_Ariston (1 use) removed from the agenda
  - 3. SD\_Bussi (1 use) removed from the agenda
  - 4. CTPht\_Ariane (1 use)
  - 5. OPE\_Boehringer (1 use)
  - 6. OPE\_Ortho (2 uses)

#### For discussion and agreement

#### Item 9 – AOB

AfA, a horizontal issue entitled "Qualification of risks to the environment for 4-ter-OP"

## RAC/50/2019/04 For discussion and agreement

#### Item 10 – Action points and main conclusions of RAC-50

Table with Conclusions and Action points from RAC-50

#### For adoption

## **PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-50 –**

## WEEK 1

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

#### Monday 9 September: Afternoon session

- Item 1 Welcome and Apologies
- Item 2 Adoption of the Agenda
- Item 3 Declarations of conflicts of interest to the Agenda
- Item 5 RAC Work Plan for Restriction, Authorisation and C&L processes
- Item 7 Restrictions

Evening session

#### **Tuesday 10 September: Morning session**

Item 7 – Restrictions

#### **Tuesday 10 September: Afternoon session**

- Item 7 Restrictions
- Item 8 Authorisation applications

#### Wednesday 11 September: Morning session

Item 7 – Restrictions

#### Wednesday 11 September: Afternoon session

Item 7 – Restrictions

Evening session

#### Thursday 12 September: Morning session

Item 8 – Authorisation applications

#### Thursday 12 September: Afternoon session

Item 8 – Authorisation applications

#### Friday 13 September: Morning session

- Item 8 Authorisation applications
- Item 5 Annual update of RAC accredited stakeholders' list
- Item 9 AOB

## **PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-50 – WEEK 2**

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

Item o	
	<b>Tuesday 17 September: Morning session</b>
Item 6	– CLH dossiers
	Tuesday 17 September: Afternoon session
Item 6	
	Wednesday 18 Contembor Merring costion
	Wednesday 18 September: Morning session
Item 6	– CLH dossiers
	Wednesday 18 September: Afternoon session
Item 6	– CLH dossiers
Evening	: Formal dinner
	Thursday 19 September: Morning session
Item 6	- CLH dossiers
	Thursday 10 Contombory Afternoon cosion
	Thursday 19 September: Afternoon session
Item 6	– CLH dossiers
	Friday 20 September: Morning session
Item 4	<ul> <li>Appointment of rapporteurs</li> </ul>
Item 6	– General CLH issues
Item 6	– CLH dossiers
Item 9	– AOB
Item 10	- Action points and main conclusions of RAC-50

#### Monday 16 September: Afternoon session

- Item 1 Welcome and Apologies
- Item 3 Declarations of conflicts of interest to the Agenda
- Item 6 CLH dossiers